Hosted on MSN5d
Trevi Therapeutics enrols all subjects in trial of Haduvio for chronic cough in IPF
US-based biopharmaceutical company Trevi Therapeutics has finished enrolling subjects in a Phase IIb trial of investigational ...
Trevi Therapeutics Completes Enrollment for Phase 2b CORAL Trial of Haduvio in Idiopathic Pulmonary Fibrosis Patients with Chronic Cough
Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy ...
Trevi Therapeutics completes enrollment for Phase 2b trial of Haduvio in cough
Trevi Therapeutics (TRVI)has completed enrollment in its Phase 2b CORAL trial of Haduvio for the treatment of chronic cough in patients with ...
Trevi Therapeutics to Participate in Upcoming March Investor Conferences
Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy ...
JonesTrading Sticks to Its Hold Rating for Spyre Therapeutics (SYRE)
JonesTrading analyst Debanjana Chatterjee reiterated a Hold rating on Spyre Therapeutics (SYRE – Research Report) today. The company’s shares ...
ETF Daily News6d
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives $9.31 Average PT from Analysts
The business’s 50-day moving average price is $4.09 and its 200-day moving average price is $3.41. Trevi Therapeutics has a 12 month low of $2.30 and a 12 month high of $5.05. About Trevi ...
ETF Daily News6d
D. Boral Capital Reaffirms Buy Rating for Trevi Therapeutics (NASDAQ:TRVI)
Trevi Therapeutics (NASDAQ:TRVI – Get Free Report)‘s stock had its “buy” rating restated by research analysts at D. Boral Capital in a research note issued to investors on Monday ...
Morningstar5d
Trevi Therapeutics to Participate in Upcoming March Investor Conferences
A Corporate presentation is available for in-person conference attendees. About Trevi Therapeutics, Inc. Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing the ...
Morningstar7d
Trevi Therapeutics Completes Enrollment for Phase 2b CORAL Trial of Haduvio in Idiopathic Pulmonary Fibrosis Patients with Chronic Cough
NEW HAVEN, Conn., Feb. 25, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral ...